Pharmasyntez group delegation took part in the BIOCHINA 2026 (11th) Forum, Asia's premier biopharmaceutical event, in Suzhou, China, from March 12–14 🧬   ⚡️Vikram Punia, Pharmasyntez group President, delivered a welcome speech at the opening of a strategic session on international cooperation on the second day of the forum. During his speech, the President gave a summary of the Russian pharmaceutical market's current situation and discussed the company's vast experience developing successful partnership strategies with Chinese counterparts.   The synergy of Chinese technological infrastructure and Russian scientific potential can accelerate the launch of innovative drugs, the President noted.   ⬆️Pharmasyntez-Nord was actively integrated into the forum's business agenda. Mikhail Kvasnikov, the CEO of the plant, and his team convened a number of working meetings to discuss future technologies and find new collaborators for joint research.   ⬆️Throughout the three days of BioChina, the Business Development Department represented by Natalya Malykh, Vice President, worked forcefully and effectively, emphasizing the importance of Russian-Chinese relations in the growth of the global pharmaceutical industry.   ✅By taking part in BIOCHINA 2026, the company can create new connections for the implementation of collaborative projects – from licensing to strategic investments. 🚀The Pharmasyntez group is consistently advancing toward its goal, which is to become a conduit for cutting-edge technologies by fusing the global best practices with high standards of Russian pharmaceuticals to improve patients' quality of life. 🧪🧪🧪🧪